News round-up for 30 January – 3 February by DDW Digital Content Editor Diana Spencer. As February 4 is World Cancer Day, this week’s update focuses on developments in the field of oncology. Drugs for lung cancer, lymphoma and breast cancer have received regulatory approvals, an investment boost will … Read More
The first and only treatment specifically indicated for patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer has been approved in the US. The Food and Drug Administration (FDA) has approved Orserdu (elacestrant) for the treatment of postmenopausal women or adult men, with ER+, HER2-, ESR1-mutated advanced… Read More
Listen to this article on the DDW podcast: Bryan Oronsky, Chief Development Officer at EpicentRx, discusses how one drug sourced from the defense and aerospace industry, could have many potential disese targets. Introduction The term “dilettante”, at least in English, connotes a sloppy bungler, a smatterer, a second rater, unskilled and… Read More
Hundreds of people with an aggressive form of lymphoma are set to benefit from the first personalised immunotherapy treatment to be recommended for routine use in the NHS. Axicabtagene ciloleucel (Yescarta, Kite) is a CAR-T therapy for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal… Read More
Listen to this article on the DDW Podcast: DDW Editor Reece Armstrong looks into recent research which may explain why cancers can become more aggressive. Researchers in London and Milan may have discovered why cancers can become more aggressive without relying only on DNA mutations. A lot of research to do… Read More
Enhertu has been approved in the EU as the first HER2 directed therapy for patients with HER2 low metastatic breast cancer. The drug is approved as monotherapy for adult patients who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within six… Read More
Listen to this article on the DDW Podcast: DDW Editor Reece Armstrong explores recent research looking into why cancer cells are so effective at avoiding the body’s immune system. Scientists may have discovered clues to why cancer cells can avoid the body’s immune system in a study conducted by researchers at… Read More
Cancer cells can shrink or super-size themselves to survive drug treatment or other challenges within their environment, researchers have discovered. Scientists at The Institute of Cancer Research, London, combined biochemical profiling technologies with mathematical analyses to reveal how genetic changes lead to differences in the size of… Read More
Listen to this article on the DDW Podcast: DDW Editor Reece Armstrong covers news of a drug which could be used to treat triple-negative breast cancer with less side effects. A less toxic treatment for a specific type of breast cancer may be on the horizon due to a new drug developed… Read More
CARsgen Therapeutics and Huadong Medicine (Hangzhou) will collaborate on the commercialisation of CARsgen's BCMA CAR-T product CT053 in mainland China. CT053 (zevorcabtagene autoleucel, Zevor-cel) is CARsgen's lead drug candidate and an autologous CAR T cell product treating relapsed/refractory multiple myeloma (R/R MM). Dr Zonghai Li, Chairman of the Board, Chief… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Clinical trials have led our news section this week, with positive results… Read More
NICE has recommended Ninlaro (ixazomib) with lenalidomide and dexamethasone as an option relapsed or refractory multiple myeloma (RRMM) in adults who have received two or three lines of therapy. Since its launch in December 2017, ixazomib has been funded through the Cancer Drugs Fund and has been used to treat… Read More
Researchers have discovered a clinical drug that sensitises glioblastoma (GBM) cells to radiotherapy and could replace the current standard of care. Scientists from Korea and the US have unveiled the mechanism of radioresistance in GBM cells, identifying therapeutic targets to overcome radioresistance. GBM is a… Read More
News round-up for 19-20 January by DDW Digital Content Editor Diana Spencer. Clinical trials have led our news section this week, with positive results announced from several Phase I and II studies. There was good news from Alto Neuroscience, everImmune, Avacta and Abionyx, though unfortunately things are not… Read More
Precision medicine uses information about an individual’s genes, proteins, and environment to prevent, diagnose, and treat diseases, including cancer. Differences in DNA, RNA, and protein can be identified in individual tissue samples, and even in individual cells. The massive data sets generated from this research have driven advances in data… Read More
This is an extraordinarily exciting time to be involved in precision medicine for cancer. This new whitepaper reviews some of the topics and trends in this emerging research area, including: 3D cultures: Spheroids and organoids Organoids in cancer research Tumour microenvironments Organ-on-a-chip and body-on-a-chip 3D bioprinting… Read More
